CTOs on the Move

BROWNING'S PHARMACY

www.brownings.net

 
BROWNING'S PHARMACY is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Melbourne, FL. To find more information about BROWNING'S PHARMACY, please visit www.brownings.net
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.brownings.net
  • 141 E Hibiscus Blvd
    Melbourne, FL USA 32901-3102
  • Phone: 321.725.6320

Executives

Name Title Contact Details

Similar Companies

Somnia Inc

Somnia Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New Rochelle, NY. To find more information about Somnia Inc, please visit www.somniainc.com

Perfect Health

Perfect Health, an independent privately held company based in Cambridge, MA, is a full service primary care practice that sees seniors in their own homes.

Autonomic Technologies

Welcome. Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache. The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013, and Autonomic Technologies was named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world.

Boys Town National Research Hospital

Boys Town National Research Hospital is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.